Mary Dolan to Antineoplastic Agents
This is a "connection" page, showing publications Mary Dolan has written about Antineoplastic Agents.
Connection Strength
6.154
-
Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022 07; 11(14):2801-2816.
Score: 0.335
-
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924.
Score: 0.278
-
Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. Clin Cancer Res. 2019 07 01; 25(13):4104-4116.
Score: 0.273
-
Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Sci Rep. 2018 01 15; 8(1):733.
Score: 0.251
-
Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS One. 2015; 10(2):e0118020.
Score: 0.205
-
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192.
Score: 0.193
-
An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet. 2012 Apr 01; 21(7):1470-80.
Score: 0.165
-
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics. 2011 Aug; 21(8):476-88.
Score: 0.160
-
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
Score: 0.160
-
The emerging role of microRNAs in drug responses. Curr Opin Mol Ther. 2010 Dec; 12(6):695-702.
Score: 0.153
-
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A. 2010 May 18; 107(20):9287-92.
Score: 0.147
-
Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics. 2010 Apr; 11(4):471-4.
Score: 0.146
-
Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
Score: 0.145
-
Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics. 2009 Jan; 3(2):128-42.
Score: 0.134
-
Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun; 64(1):133-42.
Score: 0.133
-
Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther. 2008 Nov; 327(2):442-52.
Score: 0.130
-
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics. 2008 Mar; 18(3):253-62.
Score: 0.127
-
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics. 2007 Sep; 8(9):1159-68.
Score: 0.122
-
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007 Sep; 81(3):427-37.
Score: 0.122
-
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007 Feb 01; 25(4):399-404.
Score: 0.117
-
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther. 2007 Jan; 6(1):31-6.
Score: 0.117
-
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007 Feb; 33(1):9-23.
Score: 0.115
-
Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol. 2006 Jan 12; 71(3):239-47.
Score: 0.108
-
Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics. 2005 Apr; 6(3):303-10.
Score: 0.103
-
Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):333-342.
Score: 0.100
-
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J Pharmacol Exp Ther. 2005 Jan; 312(1):206-13.
Score: 0.099
-
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004 Jun 15; 64(12):4353-6.
Score: 0.098
-
Impact of pain and adverse health outcomes on long-term US testicular cancer survivors. J Natl Cancer Inst. 2024 03 07; 116(3):455-467.
Score: 0.096
-
Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy. J Cancer Surviv. 2023 02; 17(1):27-39.
Score: 0.089
-
O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther. 2002 Sep; 1(11):943-8.
Score: 0.086
-
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
Score: 0.086
-
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec; 7(12):4239-44.
Score: 0.082
-
Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations. Hum Mol Genet. 2021 04 26; 30(3-4):305-317.
Score: 0.079
-
Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. Cancer Chemother Pharmacol. 2000; 46(2):150-5.
Score: 0.072
-
Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health. 2018 10; 2(10):744-754.
Score: 0.066
-
Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents. Anticancer Drugs. 1998 Jun; 9(5):437-48.
Score: 0.064
-
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10.
Score: 0.064
-
Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol. 1998; 41(6):505-12.
Score: 0.063
-
Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast Cancer Res Treat. 2018 Feb; 168(1):207-220.
Score: 0.062
-
Identification of Novel Protein Expression Changes Following Cisplatin Treatment and Application to Combination Therapy. J Proteome Res. 2017 11 03; 16(11):4227-4236.
Score: 0.061
-
O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997 Jun; 3(6):837-47.
Score: 0.060
-
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol. 2016 08 10; 34(23):2712-20.
Score: 0.056
-
Evaluation of inter-batch differences in stem-cell derived neurons. Stem Cell Res. 2016 Jan; 16(1):140-8.
Score: 0.054
-
Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab Dispos. 1995 Dec; 23(12):1394-9.
Score: 0.054
-
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014 Mar 12; 106(5).
Score: 0.048
-
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. Cancer Chemother Pharmacol. 1994; 35(2):121-6.
Score: 0.047
-
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
Score: 0.044
-
Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991 Jul 01; 51(13):3367-72.
Score: 0.040
-
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500.
Score: 0.040
-
Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46.
Score: 0.040
-
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72.
Score: 0.039
-
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010 Aug 04; 102(15):1114-30.
Score: 0.037
-
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009 Aug 01; 15(15):4806-14.
Score: 0.035
-
Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009 Apr 01; 23(7):877-89.
Score: 0.034
-
The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. Biochem Pharmacol. 2009 May 15; 77(10):1586-92.
Score: 0.034
-
Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des. 2009; 15(32):3782-95.
Score: 0.034
-
Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev. 2006 Jun; 32(4):261-76.
Score: 0.028
-
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther. 2004 Sep; 3(9):1127-35.
Score: 0.025
-
Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy. JAMA Oncol. 2024 Jul 01; 10(7):912-922.
Score: 0.025
-
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level. J Med Chem. 1983 Nov; 26(11):1656-9.
Score: 0.023
-
Silence is golden: gene hypermethylation and survival in large-cell lymphoma. J Natl Cancer Inst. 2002 Jan 02; 94(1):6-7.
Score: 0.021
-
Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates. Clin Cancer Res. 2000 Sep; 6(9):3662-9.
Score: 0.019
-
In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res. 2000 Feb; 6(2):737-42.
Score: 0.018
-
O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. Cancer Chemother Pharmacol. 2000; 45(6):437-40.
Score: 0.018
-
Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13.
Score: 0.017
-
Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clin Cancer Res. 2017 07 01; 23(13):3325-3333.
Score: 0.015
-
Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Cancer Res. 1994 Aug 15; 54(16):4371-5.
Score: 0.012
-
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer Res. 1994 Jul 01; 54(13):3487-93.
Score: 0.012
-
Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A. 1990 Jul; 87(14):5368-72.
Score: 0.009
-
Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine. Cancer Chemother Pharmacol. 1989; 25(2):103-8.
Score: 0.008